Administrative Coordinator, Felicia Feingersch Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. Affiliated Hospitals Medical Group Practices Practice Location 3181 Sw Sam Jackson Park Rd Portland, Oregon 97239-3011 Map and Directions Phone: (503) 314-7168 Office Hours: Monday - Friday: 8:00 AM - 5:00 PM Saturday - Sunday: Closed Dr. Box 29017 Portland, OR 97296, Portland Office 2020 SW 4th Avenue Suite 900 Portland, OR 97201. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Give Now. Where is Dr. Shivaani Kummar located? It is a privilege to be able to work in this field. Yourinsurancecompany will also be able to inform you of any copayments, coinsurance, or deductibles that will be your responsibility. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. She accepts multiple insurance plans. Only fill in if you are not human. Get to know some of the resear. They have a high school-aged daughter and middle school-aged son. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer Research', 'Montefiore Medical Center' 4 1 . Shivaani Kummar: STUDY00021766: . condition, procedure, doctor name. Before scheduling your appointment, we recommend you contact yourinsurancecompany to verify that the OHSU Health location or provider you plan to visit is included in your network. Together they form a unique fingerprint. Leadership The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Its staff of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. Keep me signed in. S Kummar, ME Gutierrez, ER Gardner, X Chen, WD Figg, M Zajac-Kaye, European journal of cancer 46 (2), 340-347, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasPhase I Trial of ABT-888 with Topotecan, Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors, Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements, Compressing drug development timelines in oncology using phase'0'trials, Wee1 kinase as a target for cancer therapy, Using cereal grain winter cover crops to reduce groundwater nitrate contamination in the mid-Atlantic coastal plain, A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter StudySD-101 Combined with Pembrolizumab in Advanced Melanoma, Cediranib for metastatic alveolar soft part sarcoma, Primary non-Hodgkin's lymphoma of the liver, Drug development in oncology: classical cytotoxics and molecularly targeted agents, A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid TumorsPhase I Study of Olaparib with Cisplatin and Gemcitabine, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerAdenosine 2A Receptor Blockade as a Cancer Immunotherapy, Advances in using PARP inhibitors to treat cancer, Clinicopathologic Features of NonSmall-Cell Lung Cancer Harboring an, Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies, Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Cited by. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. . Shivaani Kummar, MD, FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine, associate director for Clinical and Translational Research at the OHSU Knight Cancer Institute, and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Professor of Medicine, OHSU. Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute, speaks with staff members on Aug. 23, 2021. . what was bolivar's ultimate goal? In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. If you made any changes in Pure these will be visible here soon. OHSU is an equal opportunity affirmative action institution. Expanding scientific knowledge is a key mission of OHSU, Oregons only academic health center. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. The field of oncology is so broad, and theres so much to be done, Kummar says. Shivaani Kummar: STUDY00021194: A phase 1 study of SGN-CD228A in select advanced solid tumors: . Share on email. Developing new treatments for cancer is a complex, multidisciplinary process that truly takes a village. Primary Care Physicians Browse Primary Care Physiciansnear you Atlanta, GA Austin, TX Baltimore, MD Boston, MA Chicago, IL Dallas, TX Denver, CO Detroit, MI Houston, TX Dr. By Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh Carlson | American Journal of Managed Care ABSTRACTThe tropomyosin receptor kinase (TRK) family of proteins is encoded by neurotrophic tyrosine receptor kinase (NTRK) genes and has a role in the development and normal functioning of the nervous system. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. 2001-2022 Oregon Health & Science University. Spray Foam Equipment and Chemicals. Having someone who understands the challenges is helpful.. Notice of Privacy Practices He has the mindset and the clear vision to make that mindset a reality., Malhotra agrees: We speak the same language. Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. The provider is located at 3181 Sw Sam Jackson Park Rd Portland, Or 97239 and the phone number is (503) 314-7168 Which is Dr. Shivaani Kummar specialty? CET membership is open to anyone at OHSU with an interest in advancing drug discovery and development. 2001-2023 OHSU. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . Shivaani Kummar. Combining PARP Inhibitor with Immunotherapy - Does the Promise of Preclinical Data Translate to Clinic? Malhotras background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. Together their goal is to find a cure for cancer. shivaani kummar ohsu email. At the end of the day, we need to develop better treatment for cancer patients and the only way to build that is through collaboration within OHSU and with other academic centers, biotech and pharma companies., Team science can be a buzz word. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. boundtree continuing education; can you be charged under ucmj after discharge Administrative Coordinator, Margaret Rogers Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. mollie hemingway face shivaani kummar ohsu email. . Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. 2001-2023 OHSU. Dr. Kummar specializes in the care and treatment of patients with cancer. Study Purpose. lions led by donkeys for and against. This symposium is intended to be an annual event that rotates its location between Stanford University, the University of Chicago, the University of Connecticut and the Oregon Health Science University. Faculty and staff recruitment information. 2001-2023 OHSU. Nature reviews Drug discovery 9 (11), 843-856. Cited by. If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. BAL0891 . OHSU is an equal opportunity affirmative action institution. Drukers approach to team science is incorporated throughout the institutes infrastructure. Our new center will foster collaboration across disciplines, bringing together investigators interested in developing new treatments, Malhotra says. Overall: 4.7 out of 5 What is the importance of philanthropy to your work? Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. However, high costs, long development t In Brief. Patients and Methods. Early phase trials are conducted to test new treatments for cancer, while ensuring the highest standards of patient safety. What sort of projects are you working on right now? This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. My patients. Visit thebilling andinsurancesection of our sitefor more information. OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD She co-leads a team of 90 faculty members and along with her husband, Sanjay Malhotra, PhD, is focused on discovering new therapies for cancer and giving more people access to safe, experimental cancer treatments. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. 2022 ASCO Annual Meeting - Poster Session . SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. Shivaani Kummar. Shivaani Kummar Director of Center for Experimental Therapeutics, Professor and Endowed Chair, Knight Cancer Institute Each study answers scientific questions and tries to find better ways to prevent, diagnose or treat diseases like cancer. DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. Dive into the research topics where Shivaani Kummar is active. Tom Sellers was named lead research officer at OHSU Knight Cancer Institute. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . In 2014, the state of Oregon supported the OHSU Knight Cancer Challenge by providing $200 million in bonding to support building cancer research and clinical trial capacity. BYLINE. Uncategorized . This conversation is with Shivaani Kummar, MD (professor, oncology), who joined the Stanford faculty in January 2015. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. For help with all referral needs and questions, visit Referring Physicians. (h.c.), Ph.D., FAACR. Abstracts & Presentations. We have a number of clinical trials investigating promising new strategies to treat cancer. OHSU is an equal opportunity affirmative action institution. OHSU is an equal opportunity affirmative action institution. We are delighted she has chosen to join us, said Brian Druker, M.D., director of the OHSU Knight Cancer Institute. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. We are thrilled he is able to co-lead this new venture. Caring for them drives me to work harder to develop more effective treatments that are better tolerated. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP Members receive periodic email communication about events, programming, news and funding opportunities. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. OHSU Foundation P.O. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography This center will be for the community, and we hope people will reach out to be a part of it. Dr. Kummar joined the OHSU Knight Cancer Institute from Stanford University in July 2020. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Education & Training Oregon Health & Science University Fellowship, Hematology and Medical Oncology, 1995 - 1997 New York Presbyterian Hospital (Columbia Campus) Residency, Internal Medicine, 1990 - 1993 Harvard Medical School Class of 1989 A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Ashok Muralidaran, M.D., discusses how his passions inspire his work as a pediatric cardiac surgeon. Shivaani Kummar, MBBS is an Oncologist. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Shivaani Kummar (Principal Investigator, PI), OHSU Mary Crowley Cancer Research, Montefiore Medical Center 4 1 . She also leads the division of hematology & medical oncology in the OHSU School of Medicine. Shivaani Kummar. Hamburger Menu x Home The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. bard college music faculty. Verified email at ohsu.edu. 2001-2022 Oregon Health & Science University. To find better ways to treat patients. Title. ( ) (MCI) 'BAL0891' 1 27 . 5 , IND transfer 4 . 23() 'Oregon Health . OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. This new unit allows us to centralize everything in a setting designed for a patients convenience and comfort, said Patrick McCormick, M.B.A., vice president of oncology services in the Knight Cancer Institute. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. Sort. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. The Division of Hematology and Medical Oncology is headed by Shivaani Kummar, M.D., FACP and composed of many sections: Classical Hematology Community Oncology Hematologic Malignancies Palliative Care Portland VA Research Solid Tumor Stem Cell Transplantation Administration Section head Shivaani Kummar, M.D., FACP The units team of physicians, nurses, pharmacists, data coordinators and clinical research coordinators are trained and experienced in caring for people participating in cancer clinical trials. Recent external collaboration on country/territory level. Accepting new patients Shivaani Kummar, Lisa Coussens named deputy directors of OHSU Knight Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute. Their partnership will be a perfect pairing.. Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. The two will co-lead the institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . Administrative Coordinator, Ingrid Studebaker My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Over the past six months, a multidisciplinary team has been coordinating patient experience, drug delivery, staffing schedules and equipment needed to support the range of clinical trials offered in the unit that span 14 different cancer disease groups. Clinical trials Drug development oncology. Palliative Care Administrative Assistant. These new drugs go through very rigorous testing in the laboratory and only if they meet certain criteria as promising anticancer agents, we bring them forward into the first phase of human clinical trials. Kummar and Malhotra who have a high school-aged daughter and middle school-aged son met while she was faculty at Yale University. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. February 17, 2023. Administrative Coordinator, Karri Garaventa The OHSU Knight Cancer Institute is part of regional, national and international research partnerships, offering patients local access to the latest advances and clinical trials. Try restaurant style recipes at home. Shivaani KummarLisa CoussensShivaani Kummar and Lisa Coussens were named deputy directors of OHSU Knight Cancer Institute . Their mission is clear: To give patients excellent care. Username or E-mail. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. They say they shared an interest in cancer drug discovery and development that grew after their marriage. Password. Accueil; Solution; Tarif; PRO; Mon compte; France; Accueil; Solution (Getty Images), Communications Manager, OHSU Knight Cancer Institute, Husband-wife team from Stanford University tapped to lead two cancer programs at OHSU, OHSU leading effort to make cancer trials more inclusive, Making Hepatitis C care easier when treatment seems impossible, Pill for skin disease also curbs excessive drinking, OHSU clinical trial tests exercise for multiple sclerosis treatment. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. We also share information about your use of our site with our trusted social media, advertising and analytics partners. Her husband is a synthetic medicinal chemist who leads the Center for Experimental Therapeutics dedicated to discovery new cancer treatments. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. Articles Cited by Public access. Shivaani Kummar Professor Professor, Knight Cancer Institute Knight Cancer Translational Oncology Program Email kummar @ ohsu. Shivaani Kummar: STUDY00022986: An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer . The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. Dr. Kummar completed a residency at Emory University. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. (h.c.), Ph.D., FAACR Director of CEDAR Sadik Esener, Ph.D. Director of precision oncology and SMMART Gordon Mills, M.D.,Ph.D.

Willows Weep House Zillow, Articles S